Advertisement
Canadian Journal of Cardiology

Reply to Du et al.—Obvious Differences Between GLP1RAs and SGLT2is in the Outcomes of Heart Failure, Renal Failure, and Stroke

Published:September 21, 2022DOI:https://doi.org/10.1016/j.cjca.2022.09.017
      Thank you, Dr Du, for the commentary
      • Du L.
      • Wang P.
      • Chen H.
      • Zhang Y.
      • Ma J.
      Obvious differences between GLP1RAs and SGLT2is in the outcomes of heart failure, renal failure, and stroke.
      regarding our article, “The Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists on Cardiorenal Outcomes: Systematic Review and Meta-analysis.”
      • Ali M.U.
      • Mancini G.
      • Fitzpatrick-Lewis D.
      • et al.
      The effectiveness of sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists on cardiorenal outcomes: systematic review and meta-analysis.
      The differential effectiveness of the 2 classes regarding the aforementioned critical end points was highlighted in the review’s results and discussion sections. In addition, distinctions were made on a clinical basis in the guideline (published in parallel) and specifically concerning the absence of dedicated trials for GLP-1RAs in patients with heart failure or chronic kidney disease. We do emphasise, with prominence, the issue of stroke reduction with GLP-1RAs as well.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Canadian Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Du L.
        • Wang P.
        • Chen H.
        • Zhang Y.
        • Ma J.
        Obvious differences between GLP1RAs and SGLT2is in the outcomes of heart failure, renal failure, and stroke.
        Can J Cardiol. 2023; 39: 90
        • Ali M.U.
        • Mancini G.
        • Fitzpatrick-Lewis D.
        • et al.
        The effectiveness of sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists on cardiorenal outcomes: systematic review and meta-analysis.
        Can J Cardiol. 2022; 38: 1201-1210

      Linked Article